P1.21-02 Genetic Susceptibility to Immune Checkpoints Blockade Resistance

The study of cancer immunology has led to the development of immune checkpoint blockade (ICB), which transformed the treatment landscape of cancer patients. The efficacy of directed PD-(L)1 antibodies is supported by extensive clinical evidence across a wide range of tumor types, especially non-small cell lung cancer (NSCLC). Notably, the development of biomarkers for ICB has been mainly focused on tumor-related factors. However, the host immunologic status determines the response of immune-effectors against cancer cells, such as changes in circulating immune cells.